{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-061530","form_type":"8-K","ticker":"GLUE","cik":"0001826457","company_name":"Monte Rosa Therapeutics, Inc.","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.788625+00:00","generated_at":"2026-06-08T07:31:07.657839+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Monte Rosa Q3 net loss $34.9M; cash runway into H1 2026 after Roche deal and $25M offering","bullets":["Net loss $34.9M vs $27.3M in Q3 2022; R&D expenses $28.3M, G&A $8.7M.","Cash & securities $183M at Sep 30, 2023; excludes $50M Roche upfront and $25M direct offering received after quarter.","Announced interim Phase 1/2 data for MRT-2359 showing tumor reductions in MYC-driven solid tumors; RP2 dose expected Q2 2024.","Roche collaboration to discover MGDs; $50M upfront, potential milestones >$2B plus royalties.","Discontinued sickle cell program; MRT-6160 IND submission planned 1H 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-061530","json":"https://secwatch.observer/filing/0000950170-23-061530.json","markdown":"https://secwatch.observer/filing/0000950170-23-061530.md","text":"https://secwatch.observer/filing/0000950170-23-061530.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1826457/000095017023061530/0000950170-23-061530-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1826457/000095017023061530/glue-20231109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T07:31:07.657839+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"427265a29b826566edda485ad1b86fb6f823c6d6","claim":"Monte Rosa Therapeutics, Inc. reported the quarter ended September 30, 2023 results: net income Net loss for the third quarter of 2023 was $34.9 million.","evidence_excerpt":"Net loss for the third quarter of 2023 was $34.9 million, compared to $27.3 million for the third quarter of 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1826457/000095017023061530/0000950170-23-061530-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2023"},{"label":"Net income","value":"Net loss for the third quarter of 2023 was $34.9 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}